StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Nomura India Research

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byNomura India ResearchHorizon: NA (inferred 1 year)23 Oct 2026via Moneycontrol Business (broker lists)

Entry₹1,129.4Inferred
Target₹1,450
Total upside +28.39%
Stop lossNot given
CMP₹1,189.91d ago
Active+5.36%+21.86%upside left 11 mo left
Follow Nomura India Research for new calls(100% target hit, 39 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 12 other Long-term calls on ZYDUSLIFESee 273 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:39 am IST
39 supporting11 neutral12 opposing
Supports the BUY call (39)

Zydus Lifesciences announced the closure of a USFDA inspection at its Zydus LiqMeds facility in the UK.

NSE · Press Release·14 Nov · today

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·13 Nov · yesterday

Zydus Lifesciences has completed the subscription of shares and the formation of a 50:50 joint venture with Sunshine Healthcare Lanka Limited in Zydus Sunshine Lifesciences, effective November 11, 202

BSE · Company Update·12 Nov · 2d ago

(opens in new tab)

Zydus Lifesciences, Granules India offer growth opportunities over next 3-5 years: Shanika Capital

NewsCnbc-Tv18·9 Nov · 5d ago

(opens in new tab)

Shanika Capital's Anmol Ganjoo sees Zydus Lifesciences, Granules India among potential pharma winner

NewsCnbc-Tv18·9 Nov · 5d ago

(opens in new tab)
Neutral / worth noting (11)

Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 1w ago

(opens in new tab)
Weighs against the BUY call (12)

Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore

NewsEt-Markets·5 Nov · 1w ago

(opens in new tab)

Zydus Lifesciences Q2 Results: Shares fall after profit drops 27%, margins contract

NewsCnbc-Tv18·4 Nov · 1w ago

(opens in new tab)

Zydus Lifesciences reported Q2 FY27 consolidated net profit of Rs 9,255 million, down 27% year-on-year, with EBITDA down 6% to Rs 18,945 million. Revenue grew 29% to Rs 79,096 million.

BSE · Company Update·4 Nov · 1w ago

(opens in new tab)

Zydus Lifesciences reported Q2 FY27 consolidated net profit of Rs 9,255 million, down 27% year-on-year, and EBITDA of Rs 18,945 million, down 6% year-on-year.

NSE · Press Release·4 Nov · 1w ago

(opens in new tab)

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Nomura India Research

Every call and its outcome